Akthelia and University of Iceland lead €6M EU-funded initiative to battle antimicrobial resistance

In a significant boost to Europe’s biotech innovation ecosystem, Akthelia Pharmaceuticals, an Iceland-based preclinical-stage drug developer, has been awarded a €6 million Horizon Europe grant alongside the University of Iceland for their collaborative project IN-ARMOR. The funding announcement, made on April 19, 2023, places the initiative at the forefront of European efforts to tackle one of the world’s most pressing public health threats: antimicrobial resistance (AMR).

The IN-ARMOR project is structured around pioneering research into novel innate immune system inducers, designed to mitigate the global burden of bacterial, viral, and fungal infections—particularly those deemed as high-priority by global health agencies. It is projected to play a key role in reducing dependence on traditional antibiotic development while offering a scalable model for immune-based anti-infective therapies.

What is the IN-ARMOR project and why is it critical for combating antimicrobial resistance?

IN-ARMOR, short for Innate Armor Against Resistant Microbes, seeks to develop a new class of drug candidates that enhance the body’s own immune response to pathogens. Rather than focusing on the traditional pharmaceutical model of killing bacteria directly with antibiotics, the project pivots to stimulating the innate immune system using immune modulators. This approach not only reduces the evolutionary pressure that fosters resistance but may also broaden the therapeutic target range to include viruses and fungi.

The global implications are vast. Akthelia Pharmaceuticals has estimated that successful outcomes from IN-ARMOR could result in a long-term cost saving of approximately €107 billion by reducing antibiotic production, hospitalizations, and chronic infections. Additionally, the project claims potential to cut global disease burden by up to 97 million disability-adjusted life years (DALYs), based on epidemiological models correlating AMR trends with treatment access.

According to the World Health Organization (WHO), AMR contributes to more than five million deaths annually and is considered one of the top 10 public health threats to humanity. Among the pathogens being targeted by the IN-ARMOR platform are two of the WHO’s Priority 1 (Critical) bacteria, against which existing drugs are proving increasingly ineffective.

How will Akthelia’s drug discovery strategy integrate nanotech and AI in this program?

Akthelia Pharmaceuticals is spearheading a cutting-edge drug discovery platform that integrates computer-aided molecular design, in-silico simulations, and nanotechnology-driven drug delivery. The core of the IN-ARMOR project will build on this hybrid platform to refine therapeutic candidates and validate them through both preclinical and early-phase clinical testing.

The approach allows for molecular optimization and predictive modeling of immune activators, reducing time and cost typically associated with early-stage drug development. Nanotech-based delivery systems, such as targeted nanoparticle vectors, will be explored to enhance bioavailability and tissue-specific activation, a crucial factor for therapies designed to stimulate localized immune responses in infected or inflamed tissue.

This high-tech drug design model could allow Akthelia to overcome longstanding challenges in AMR therapy: poor drug penetration, toxicity issues, and lack of efficacy in immunocompromised patients.

Which institutions and partners are involved in the pan-European IN-ARMOR consortium?

The IN-ARMOR initiative is not limited to Icelandic institutions. It comprises a broad-based European network of 16 participating entities—spanning nine universities and research institutes as well as seven industrial and medical partners. These collaborators are distributed across nine EU member states, forming a multidisciplinary innovation ecosystem that blends academic microbiology, pharmaceutical R&D, clinical trial infrastructure, and public health implementation.

Although a complete list of partner names has not been released at this stage, the scope includes early translational labs, clinical trial centers, and pharmaceutical manufacturers with interest in immunotherapeutics and infectious disease solutions. The consortium will oversee laboratory discovery, animal model validation, and early human safety trials, working in tandem with regulatory agencies to streamline compliance with EMA (European Medicines Agency) standards.

What role does the EU’s Horizon Europe program play in funding biotechnology against AMR?

Horizon Europe, the European Union’s €95.5 billion flagship funding program for research and innovation, is a critical financial engine behind projects like IN-ARMOR. By allocating €6 million to Akthelia Pharmaceuticals and its academic and industrial partners, the European Commission underscores its strategic priority to tackle antimicrobial resistance at the root rather than through reactive drug pipelines.

This grant falls under Horizon Europe’s “Health” cluster, specifically targeting tools to combat infectious diseases and fortify public health resilience. Given the WHO’s repeated alerts about the potential for AMR to undermine modern medicine—from routine surgeries to chemotherapy—the EU has prioritized public-private partnerships that can deliver actionable medical countermeasures within this decade.

Funding terms also support scalability, enabling the IN-ARMOR project to potentially expand into larger Phase II or Phase III clinical trials in future Horizon cycles, contingent on early-stage success.

How is Akthelia Pharmaceuticals positioning itself as a next-generation anti-infective innovator?

Led by CEO Egill Masson, Akthelia Pharmaceuticals is rapidly emerging as one of Iceland’s most ambitious biotechnology developers. The firm’s focus on innate immunity—rather than direct pathogen-targeting drugs—sets it apart from traditional antibiotic companies. This strategic differentiation positions the Icelandic biotech firm favorably in a global market increasingly interested in non-antibiotic solutions to drug resistance.

In a public statement, Masson expressed strong optimism about the grant, noting that “the IN-ARMOR project focuses on novel immune system inducers and is a testament to the potential of our approach to address the global challenge of antimicrobial resistance.” He further added that the funding will allow the company to target “not only infections caused by bacteria but also inflammation and the challenge of viral and fungal infections, where fewer treatment options exist.”

Akthelia is still in the preclinical stage of development, but its use of artificial intelligence, immunological insight, and precision nanotechnology is earning it increased attention among early-stage investors and public health stakeholders alike.

What are the projected outcomes and public health implications of the IN-ARMOR project?

The most immediate objective for Akthelia and its IN-ARMOR partners is to validate their lead immune modulators in preclinical systems, followed by early-phase human trials focused on safety and immunological efficacy. If the immune inducers show promising results against high-priority AMR pathogens, they could eventually be fast-tracked under regulatory incentives designed to accelerate antimicrobial innovation.

From a macroeconomic perspective, the project could reshape how Europe approaches infectious disease preparedness. By shifting investment from narrow-spectrum antibiotics to immune-boosting therapies with broad applicability, healthcare systems may not only reduce the burden of hospital-acquired infections but also improve patient outcomes in immunocompromised populations.

A successful IN-ARMOR rollout could also serve as a blueprint for other EU-funded biotech consortia aiming to combat health emergencies through next-gen drug design.

What is the broader significance of immune-based therapies in the fight against AMR?

While antibiotics will likely remain a necessary tool in the clinical arsenal, the IN-ARMOR project exemplifies a growing global shift toward host-directed therapies that minimize resistance pressure. As pathogens continue to evolve, strategies that empower the human immune system offer a longer-term, sustainable solution to infectious disease.

In this context, Akthelia Pharmaceuticals and the University of Iceland are positioning their science at the convergence of immunology, technology, and public health—an intersection that could redefine how we understand and manage drug-resistant infections.